Shaorong Li
7 Papers
Shaorong Li is an academic researcher. The author has contributed to research in topics: Medicine & Pharmacokinetics. The author has an hindex of 1, co-authored 5 publications.
Chat about Author
Papers
Tolerability, safety, and preliminary antitumor activity of fuzuloparib in combination with SHR-1316 in patients with relapsed small cell lung cancer: a multicenter, open-label, two-stage, phase Ib trial
Yanjun Xu,Zhiyu Huang,Jian Fang,Anwen Liu,Hongyang Lu,Xinmin Yu,Kaiyan Chen,Xiaoling Xu,Wei Shi,Young Hak Kim,Taiki Hakozaki,Alfredo Addeo,Yuang-Kuang Shen,Shaorong Li,Yun Fan +14 more
TL;DR: Fuzuloparib combined with SHR-1316 failed to improve the outcomes in unselected patients with relapsed SCLC and a recommended phase II dose (RP2D) was introduced in the stage 2 expansion phase.
5
Evaluation of the Effect of Food on the Pharmacokinetics of SHR6390, An Oral CDK4/6 Inhibitor, in Healthy Volunteers
Yanping Liu,M. Hu,Ping-Ping Lin,Ting Li,Shuqin Liu,Yu-ya Wang,Shaorong Li,Xiang-kun Li,Chenjing Wang,Yu Cao +9 more
TL;DR: Wang et al. as mentioned in this paper evaluated the effect of food on the pharmacokinetics of SHR6390 tablets and found that food intake increased the maximum plasma concentration, AUC0−t, and AUC 0−∞ significantly compared with the fasting condition.
A mass balance study of [14C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans
Hua Zhang,Shu Yan,Yan Zhan,Shengyao Ma,Yicong Bian,Shaorong Li,J Tian,Guangze Li,Dafang Zhong,Xingxing Diao,Liyan Miao +10 more
TL;DR: Wang et al. as mentioned in this paper investigated the metabolism, mass balance, and pharmacokinetics of SHR6390 in 6 healthy Chinese male subjects after a single oral dose of 150 mg.
3
Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study
Yuxiang Ma,Qun Chen,Yang Zhang,Jinhui Xue,Qianwen Liu,Yuanyuan Zhao,Yunpeng Yang,Yan Huang,Wenfeng Fang,Zhiguo Hou,Shaorong Li,Jing Wang,Li Zhang,Hongyun Zhao +13 more
TL;DR: Similar PFS and grade of treatment-emergent adverse events (TEAEs) were found between different Cmax and AUC0−τ of apatinib and gefitinib at 500 mg apatinIB and 250 mg gefITinib dose levels, and Apatinib pharmacokinetics parameters were not significantly changed when coadministered with gefithinib.
2
Effect of Dietary Intake on the Pharmacokinetics of the Multitargeted Receptor Tyrosine Kinase Inhibitor Famitinib: Results From a Phase 1 Study in Healthy Chinese Participants
Xiaoran Zhang,Gexin Shi,Shaorong Li,Jing Rao,Qing Wen,Heng-Li Zhao +5 more
TL;DR: Wang et al. as discussed by the authors investigated the effect of high-fat or low-fat food intake on the single-dose pharmacokinetic properties of oral famitinib, which is a tyrosine kinase inhibitor under clinical investigation for the treatment of solid tumors.